Cancer Letters
Volume 305, Issue 2 , Pages 228-238 , 28 June 2011

Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma

  • Sung Soo Kim

      Affiliations

    • Department of Internal Medicine, Uijongbu St. Mary Hospital, Catholic University of Korea, Seoul, Republic of Korea
    • ,
  • Victoria E. Ruiz

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Rhode Island Hospital and Brown University, Providence, RI, United States
    • ,
  • Jaqueline D. Carroll

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Rhode Island Hospital and Brown University, Providence, RI, United States
    • ,
  • Steven F. Moss

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Rhode Island Hospital and Brown University, Providence, RI, United States
    • Corresponding Author InformationCorresponding author. Address: Gastroenterology Division, Rhode Island Hospital 593 Eddy Street, APC 414, Providence, RI 02903. Tel.: +1 401 444 6713; fax: +1 401 444 2939.

Received 1 April 2010 ,Revised 11 July 2010 ,Accepted 13 July 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. J. Clin. 2002;55(2005):74–108
  2. Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer. Surg. Clin. North Am. 2009;89:79–96VIII
  3. Du MQ, Atherton JC. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut. 2006;55:886–893
  4. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 2006;118:3030–3044
  5. Suerbaum S, Michetti P. Helicobacter pylori infection. New Engl. J. Med. 2002;347:1175–1186
  6. Peek Jr RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer. 2002;2:28–37
  7. IARC Working Group, Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. lyon, 7–14 June 1994, IARC Monogr. Eval. Carcinog. Risks Hum. 61 (1994) 1–241.
  8. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Pract. Oncol. 2005;2:90–97(quiz 1 p following 113)
  9. Hill P, Rode J. Helicobacter pylori in ectopic gastric mucosa in Meckel’s diverticulum. Pathology. 1998;30:7–9
  10. Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, Fiocca R, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology. 2007;132:1009–1023
  11. Dubois A, Boren T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cell Microbiol. 2007;9:1108–1116
  12. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology. 2008;134:306–323
  13. Sycuro LK, Pincus Z, Gutierrez KD, Biboy J, Stern CA, Vollmer W, et al. Peptidoglycan crosslinking relaxation promotes Helicobacter pylori’s helical shape and stomach colonization. Cell. 2010;141:822–833
  14. Falush D, Wirth T, Linz B, et al. Traces of human migrations in Helicobacter pylori populations. Science. 2003;299:1582–1585
  15. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547
  16. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547
  17. McClain MS, Shaffer CL, Israel DA, Peek Jr RM, Cover TL. Genome sequence analysis of Helicobacter pylori strains associated with gastric ulceration, gastric cancer. BMC Genom. 2009;10:3
  18. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999;397:176–180
  19. Baltrus DA, Amieva MR, Covacci A, Lowe TM, Merrell DS, Ottemann KM, et al. The complete genome sequence of Helicobacter pylori strain G27. J. Bacteriol. 2009;191:447–448
  20. Oh JD, Kling-Backhed H, Giannakis M, et al. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc. Natl. Acad. Sci. USA. 2006;103:9999–10004
  21. Thiberge JM, Boursaux-Eude C, Lehours P, et al. Array-based hybridization of Helicobacter pylori isolates to the complete genome sequence of an isolate associated with MALT lymphoma. BMC Genom. 2010;11:368
  22. Israel DA, Salama N, Krishna U, Rieger UM, Atherton JC, Falkow S, et al. Helicobacter pylori genetic diversity within the gastric niche of a single human host. Proc. Natl. Acad. Sci. USA. 2001;98:14625–14630
  23. Higashi H, Yokoyama K, Fujii Y, Ren S, Yuasa H, Saadat I, et al. EPIYA motif is a membrane-targeting signal of Helicobacter pylori virulence factor CagA in mammalian cells. J. Biol. Chem. 2005;280:23130–23137
  24. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J. Biol. Chem. 1992;267:10570–10575
  25. Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology. 2008;135:91–99
  26. Sharma CM, Hoffmann S, Darfeuille F, et al. The primary transcriptome of the major human pathogen Helicobacter pylori. Nature. 2010;464:250–255
  27. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60
  28. Helicobacter and Cancer Collaborative Group, Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts, Gut 49 (2001) 347–353.
  29. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest. 2009;119:2475–2487
  30. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?. Ann. Internal Med. 2009;151:121–128
  31. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–397
  32. Fock KM, Katelaris P, Sugano K, et al. Second asia–pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009;24:1587–1600
  33. Yamaoka Y. Helicobacter pylori typing as a tool for tracking human migration. Clin. Microbiol. Infect. 2009;15:829–834
  34. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2003;125:1636–1644
  35. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR. Variants of the 3’ region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J. Clin. Microbiol. 1998;36:2258–2263
  36. Ogiwara H, Graham DY, Yamaoka Y. VacA i-region subtyping. Gastroenterology. 2008;134:1267;(author reply 1268)
  37. Franco AT, Johnston E, Krishna U, Yamaoka Y, Israel DA, Nagy TA, et al. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res. 2008;68:379–387
  38. Fox JG, Wang TC, Rogers AB, et al. Host and microbial constituents influence Helicobacter pylori-induced cancer in a murine model of hypergastrinemia. Gastroenterology. 2003;124:1879–1890
  39. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol. 2008;10:1573–1581
  40. Saadat I, Higashi H, Obuse C, et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature. 2007;447:330–333
  41. Cascales E, Christie PJ. The versatile bacterial type IV secretion systems. Nat. Rev. Microbiol. 2003;1:137–149
  42. Viala J, Chaput C, Boneca IG, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 2004;5:1166–1174
  43. Watanabe T, Asano N, Fichtner-Feigl S, Gorelick PL, Tsuji Y, Matsumoto Y, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway. J. Clin. Invest. 2010;120:1645–1662
  44. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc. Natl. Acad. Sci. USA. 2008;105:1003–1008
  45. Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology. 2007;133:926–936
  46. Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res. 2009;69:6164–6170
  47. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology. 1998;115:642–648
  48. Romero-Gallo J, Harris EJ, Krishna U, Washington MK, Perez-Perez GI, Peek RM. Effect of Helicobacter pylori eradication on gastric carcinogenesis, laboratory investigation. J. Tech. Methods Pathol. 2008;88:328–336
  49. Rogers AB, Taylor NS, Whary MT, Stefanich ED, Wang TC, Fox JG. Helicobacter pylori but not high salt induces gastric intraepithelial neoplasia in B6129 mice. Cancer Res. 2005;65:10709–10715
  50. Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology. 2005;128:1937–1952
  51. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408–419
  52. Hahm KB, Lee KM, Kim YB, et al. Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol. Ther. 2002;16(2):115–127
  53. Kuzushita N, Rogers AB, Monti NA, Whary MT, Park MJ, Aswad BI, et al. P27kip1 deficiency confers susceptibility to gastric carcinogenesis in Helicobacter pylori-infected mice. Gastroenterology. 2005;129:1544–1556
  54. Rogers AB, Houghton J. Helicobacter based mouse models of digestive system carcinogenesis. In:  Kozlov SV editors. Inflammation in Cancer. Methods in Molecular Biology. Humana Press; 2009;
  55. Liu H, Merrell DS, Semino-Mora C, Goldman M, Rahman A, Mog S, et al. Diet synergistically affects Helicobacter pylori-induced gastric carcinogenesis in nonhuman primates. Gastroenterology. 2009;137:1367–1379(e1–6)
  56. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990;50:7415–7421
  57. Chaturvedi R, Asim M, Lewis ND, Algood HM, Cover TL, Kim PY, et al. l-arginine availability regulates inducible nitric oxide synthase-dependent host defense against Helicobacter pylori. Infect. Immun. 2007;75:4305–4315
  58. Ding SZ, Minohara Y, Fan XJ, Wang J, Reyes VE, Patel J, et al. Helicobacter pylori infection induces oxidative stress and programmed cell death in human gastric epithelial cells. Infect. Immun. 2007;75:4030–4039
  59. Bhattacharyya A, Chattopadhyay R, Burnette BR, Cross JV, Mitra S, Ernst PB, et al. Acetylation of apurinic/apyrimidinic endonuclease-1 regulates Helicobacter pylori-mediated gastric epithelial cell apoptosis. Gastroenterology. 2009;136:2258–2269
  60. Touati E, Michel V, Thiberge JM, Wuscher N, Huerre M, Labigne A. Chronic Helicobacter pylori infections induce gastric mutations in mice. Gastroenterology. 2003;124:1408–1419
  61. Jenks PJ, Jeremy AH, Robinson PA, Walker MM, Crabtree JE. Long-term infection with Helicobacter felis and inactivation of the tumour suppressor gene p53 cumulatively enhance the gastric mutation frequency in big blue transgenic mice. J. Pathol. 2003;201:596–602
  62. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007;13:470–476
  63. Shirin H, Weinstein IB, Moss SF. Effects of H. pylori infection of gastric epithelial cells on cell cycle control. Front. Biosci. 2001;6:E104–E118
  64. Mimuro H, Suzuki T, Nagai S, et al. Helicobacter pylori dampens gut epithelial self-renewal by inhibiting apoptosis A bacterial strategy to enhance colonization of the stomach. Cell Host Microbe. 2007;2:250–263
  65. Houghton JM, Bloch LM, Goldstein M, Von Hagen S, Korah RM. In vivo disruption of the fas pathway abrogates gastric growth alterations secondary to Helicobacter infection. J. Infect. Dis. 2000;182:856–864
  66. Shirin H, Sordillo EM, Kolevska TK, et al. Chronic Helicobacter pylori infection induces an apoptosis-resistant phenotype associated with decreased expression of p27(kip1). Infect. Immun. 2000;68:5321–5328
  67. Wei J, O’Brien D, Vilgelm A, Piazuelo MB, Correa P, Washington MK, et al. Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology. 2008;134:1412–1423
  68. Resnick MB, Sabo E, Meitner PA, Kim SS, Cho Y, Kim HK, et al. Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. Gut. 2006;55:1717–1724
  69. Moss SF, Lee JW, Sabo E, et al. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin. Cancer Res. 2008;14:4161–4167
  70. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin. Gastroenterol. Hepatol. 2006;4:416–425
  71. Chan AO, Peng JZ, Lam SK, Lai KC, Yuen MF, Cheung HK, et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut. 2006;55:463–468
  72. Sepulveda AR, Yao Y, Yan W, Park DI, Kim JJ, Gooding W, et al. CpG methylation and reduced expression of O(6)-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology. 2010;138:1836–1844
  73. Nakajima T, Enomoto S, Yamashita S, Ando T, Nakanishi Y, Nakazawa K, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J. Gastroenterol. 2010;45:37–44
  74. Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010;70:1430–1440
  75. Xia G, Schneider-Stock R, Diestel A, Habold C, Krueger S, Roessner A, et al. Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem. Biophys. Res. Commun. 2008;369:526–531
  76. Belair C, Darfeuille F, Staedel C. Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship. Clin. Microbiol. Infect. 2009;15:806–812
  77. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M, et al. MicroRNA signatures in Helicobacter pylori-infected gastric mucosa. Int. J. Cance. 2010;
  78. Fassi Fehri L, Koch M, Belogolova E, et al. Helicobacter pylori induces miR-155 in T cells in a cAMP-Foxp3-dependent manner. PLoS One. 2010;5:e9500
  79. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. MiR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008;88:1358–1366
  80. Xiao B, Liu Z, Li BS, et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J. Infect. Dis. 2009;200:916–925
  81. Sanduleanu S, Jonkers D, de Bruine A, Hameeteman W, Stockbrugger RW. Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. Dig. Liver Dis. 2001;33:707–719
  82. Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. New Engl. J. Med. 1996;335:242–249
  83. Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann. Med. 1995;27:569–573
  84. Algood HM, Gallo-Romero J, Wilson KT, Peek Jr RM, Cover TL. Host response to Helicobacter pylori infection before initiation of the adaptive immune response. FEMS Immunol. Med. Microbiol. 2007;51:577–586
  85. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306:1568–1571
  86. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402
  87. Gianfagna F, De Feo E, van Duijn CM, Ricciardi G, Boccia S. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr. Genom. 2008;9:361–374
  88. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. New Engl. J. Med. 1994;330:1267–1271
  89. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J. Pathol. 1996;178:122–127
  90. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin. Gastroenterol. Hepatol. 2010;8:105–110
  91. Hausen HZ. Infections Causing Human Cancer. first ed.. Weinheim: Wiley-VCH; 2006;

PII: S0304-3835(10)00362-9

doi: 10.1016/j.canlet.2010.07.014

Cancer Letters
Volume 305, Issue 2 , Pages 228-238 , 28 June 2011

Article Tools

* Image Usage & Resolution